TargetMol

15-(6-nitroxyhexanoyl)-17-phenyl trinor Prostaglandin F2 α

Product Code:
 
TAR-T36908
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T36908-1mg1mg£167.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T36908-5mg5mg£304.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T36908-10mg10mg£470.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
15-(6-nitroxyhexanoyl)-17-phenyl trinor Prostaglandin F2α(15-(6-nitroxyhexanoyl)-17-phenyl trinor PGF2α) is a nitric oxide-donating derivative of 17-phenyl trinor PGF2α.1It increases cGMP levels in rabbit aqueous humor and iris ciliary body when topically administered at a concentration of 0.042%. Topical administration of 15-(6-nitroxylhexanoyl)-17-phenyl trinor PGF2α(0.14%) reduces intraocular hypertension (IOP) in a rabbit model of hypertonic saline-induced transient ocular pressure. It also reduces IOP in a cynomolgus monkey model of laser-induced ocular hypertension when administered topically at a concentration of 0.042%.
CAS:
1194396-71-8
Formula:
C31H46N2O8
Molecular Weight:
574.7
Purity:
0.98
SMILES:
O[C@@H]1C[C@H](O)[C@H](C/C=CCCCC(NCC)=O)[C@H]1/C=C/[C@H](CCC2=CC=CC=C2)OC(CCCCCO[N+]([O-])=O)=O

References

Impagnatiello, F., Toris, C.B., Batugo, M., et al.Intraocular pressure-lowering activity of NCX 470, a novel nitric oxide-donating bimatoprost in preclinical modelsInvest. Ophthalmol. Vis. Sci.56(11)6558-6564(2015)